BioNTech

Preço: 90.54

Empresa e modelo de negócios

BioNTech is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Its core products include mRNA-based vaccines, notably the COVID-19 vaccine developed in partnership with Pfizer. Major business segments encompass vaccine development, oncology therapies, and research collaborations. The primary revenue source has been from vaccine sales, particularly during the pandemic, although recent financial reports indicate a significant decline in revenue.

Perfil de investimento

The investment profile of BioNTech is more aligned with growth investors, given its focus on innovative therapies and potential for future product development. However, the recent decline in revenue and negative earnings per share suggest increased risk, making it less suitable for conservative investors. The stock may appeal to those with a higher risk tolerance looking for long-term growth opportunities.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $: -5.09 Risco
Receita QoQ — crescimento da receita trimestre contra trimestre: -86.6% ↓
Surpresa de EPS: 3.7% em linha
Volatilidade 20d: 1.9% estável

Dados FMP / FinFeed atualizados: 2026-06-11

Impacto da previsão

neutro

Rating elevado · UBS · válido até 2026-06-26 · atualizado 2026-06-13

Alvo +49.1% preenchimento do alvo 67.1%

Reação D5 -1.67% · D10 -5.82%

Impacto Potencial 0 · Risco 0 até 30 dias ou até o alvo ser atingido

Rec.: Vender Potencial: 30 Risco: 73 Atualizado: 2026-06-13 02:36

Como a recomendação funciona

Por que a IA pensa assim:

Weak fundamentals and negative momentum raise significant concerns.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell

Mudanças na recomendação da IA

Data	Antes	Depois	Motivo
2026-05-12 02:57	Manter	Vender	scenario_deterioration
2026-05-08 15:29	—	Manter	Weak fundamentals and negative momentum signal high risk.
2026-05-08 05:27	Manter	Manter	Компания демонстрирует значительное снижение выручки и отрицательный EPS, что указывает на финансовые трудности. Текущие тренды и высокая волатильность делают инвестиции в BioNTech рискованными.
2026-04-17 02:54	Vender	Manter	Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на высокие риски. Однако недавний рост цены акций может свидетельствовать о восстановлении интереса инвесторов.
2026-03-22 07:36	Manter	Vender	scenario_deterioration
2026-03-11 05:26	—	Manter	Компания испытывает значительное падение цен на акции и нестабильность в финансовых показателях, что указывает на высокие риски для инвесторов.

Previsões de analistas

Data	Analista	Action	Alvo	Preço na época
2026-05-27 08:43	UBS	Rating elevado	— → 135	92.25
2026-05-21 20:24	Bernstein	Atualizar	— → 96	90.93
2026-05-06 11:32	Canaccord Genuity	Preço-alvo reduzido	171 → 158	95.5
2026-04-10 12:55	Morgan Stanley	Preço-alvo elevado	125 → 126	93.381
2026-03-11 13:15	BMO Capital	Preço-alvo reduzido	— → 128	90.52
2026-03-10 19:41	Jefferies	Preço-alvo reduzido	— → 138	83.89
2026-03-10 18:28	Truist Financial	Atualizar	— → 155	83.89
2026-03-10 16:29	Morgan Stanley	Preço-alvo reduzido	— → 128	83.89
2026-02-02 11:03	Leerink Partners	Rating rebaixado	— → 113	113.75
2026-01-16 11:49	Goldman Sachs	Rating elevado	— → 142	106.07
2025-12-11 17:03	Berenberg Bank	Preço-alvo elevado	150 → 155	95.68
2025-12-11 11:43	H.C. Wainwright	Atualizar	— → 140	96.91
2025-11-03 19:21	Morgan Stanley	Preço-alvo elevado	131 → 134	103.955

Nada ainda